Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
03/2014
03/12/2014CN102167687B Compound and application thereof in preparation of anti-tumor pharmaceutical, food or cosmetic
03/12/2014CN102137666B Chemical compounds 251
03/12/2014CN102112146B Immunity inducer
03/12/2014CN102085377B Immunogenic composition and methods
03/12/2014CN102060875B Quinazoline derivative, and preparation method and application thereof
03/12/2014CN101891775B 6-hydroxy-2-O-beta-D-glucopyranose base heptane, and preparation method and application thereof
03/12/2014CN101884784B Bv8 nucleic acids and polypeptides with mitogenic activity
03/12/2014CN101880688B Method for selectively replicating replication-defective adenovirus and application
03/12/2014CN101880381B Segmented copolymer modified by polyethylene glycol 1000 vitamin E succinic acid ester, preparation method and applications thereof
03/12/2014CN101863903B 1,4-dihydrobithiophene [3', 2': 5, 6] bithiapyran [4, 3-c] pyrazol-3-carboxylic acid derivative and application thereof
03/12/2014CN101801973B 6-triazolopyridazinesulfanyl benzothiazole and benzimidazole derivatives, method for production thereof and application as medicaments and pharmaceutical compositions and use as met inhibitors
03/12/2014CN101720318B Quinazolin-oxime derivatives as Hsp90 inhibitors
03/12/2014CN101675053B Phosphoinositide 3-kinase inhibitor compounds and methods of use
03/12/2014CN101541960B Partial fragment of REIC/Dkk-3 gene and therapeutic agent for cancer containing same
03/12/2014CN101460054B Mature dendritic cell compositions and methods for culturing same
03/12/2014CN101418044B Immunoglobulin variants and uses thereof
03/11/2014US8669376 Cytotoxin compounds and methods of isolation
03/11/2014US8669293 Method and compositions for preventing hormone induced adverse effects
03/11/2014US8669237 Biodegradable immunomodulatory formulations and methods for use thereof
03/11/2014US8669231 Activation of peptide prodrugs by hK2
03/11/2014US8669081 Compositions useful as inhibitors of protein kinases
03/11/2014CA2784180C Seven-membered ring compound and pharmaceutical use therefor
03/11/2014CA2674780C Compounds with (substituted phenyl)-propenal moiety, their derivatives, biological activity, and uses thereof
03/11/2014CA2655801C Therapeutic or prophylactic agent for leukemia
03/11/2014CA2599150C Anticancer agent comprising paclitaxel and a diptheria toxin mutant, crm 197
03/11/2014CA2567449C Antibodies and related molecules that bind to psca proteins
03/11/2014CA2501932C Use of benzimidazole quinolinones for treating cancer
03/11/2014CA2422429C A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
03/11/2014CA2418899C Use of immunogens to treat or prevent malignant breast tumours, immune or vascular system disorders stemming from extra-cellular factors
03/11/2014CA2396428C Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
03/11/2014CA2375912C Immunotherapy of autoimmune disorders using antibodies which target b-cells
03/06/2014WO2014036534A1 Curcumin-er, a liposomal-plga sustained release nanocurcumin for minimizing qt prolongation for cancer therapy
03/06/2014WO2014036426A1 N-(3-fluorobenzyl)-2-(5-(4-morpholinophenyl)pyridin-2-yl) acetamide as protein|tyrosine kinase modulators
03/06/2014WO2014036393A1 A method to improve pharmacokinetics of drugs
03/06/2014WO2014036022A1 Quinazolinone compounds and derivatives thereof
03/06/2014WO2014036015A1 Serine/threonine kinase inhibitors for the treatment of hyperproliferative|diseases
03/06/2014WO2014035474A1 Compositions and methods for treating cancer
03/06/2014WO2014035345A1 Peptides and uses thereof
03/06/2014WO2014035149A1 N-acylhydrazone derivatives for selective t cell inhibitor and anti-lymphoid malignancy drug
03/06/2014WO2014035060A1 Composition for preventing or treating cancer containing extracts of artocarpus altilis fruits, leaves, or stems, or fractions thereof as active ingredients
03/06/2014WO2014034922A1 Peptide for inhibiting vascular endothelial growth factor receptor
03/06/2014WO2014034898A1 Pyridine derivative and medicine
03/06/2014WO2014034798A1 Method for detection of cancer, diagnostic drug and diagnostic kit for cancer, and pharmaceutical composition for treatment of cancer
03/06/2014WO2014034754A1 Psf1-derived peptide
03/06/2014WO2014034735A1 Dna vaccine containing vegf-specific epitope and/or angiopoietin-2-specific epitope
03/06/2014WO2014034700A1 CELL PROLIFERATION REGULATION COMPOSITION CONTAINING PEPTIDE COMPRISING PARTIAL AMINO ACID SEQUENCE FOR BBF2H7 (BBF2 human homologue on chromosome7) OR ANTIBODY CAPABLE OF BINDING TO SAID PEPTIDE
03/06/2014WO2014034669A1 Lipid membrane structure including bacterial cell component having dispersibility in non-polar solvent, and method for producing same
03/06/2014WO2014034609A1 P53 family chimeric molecule and use thereof
03/06/2014WO2014033631A1 N-(3-pyridyl) biarylamides as kinase inhibitors
03/06/2014WO2014033630A1 Novel aminothiazole carboxamides as kinase inhibitors
03/06/2014WO2014033597A1 5-azaindole compounds with anticancer and antiangiogenic activities
03/06/2014WO2014033497A1 5-azaindole compounds with anticancer and antiangiogenic activities
03/06/2014WO2014033366A1 Pharmaceutical compositions of anisomelic acid and the use thereof
03/06/2014WO2014033196A1 Dioxino- and oxazin-[2,3-d]pyrimidine pi3k inhibitor compounds and methods of use
03/06/2014WO2014033136A1 Aminoheteroaryl compounds as mth1 inhibitors
03/06/2014WO2014032782A1 Jagaricin derivatives and their use as fungicide or antitumor agent
03/06/2014WO2014032498A1 Highly selective c-met inhibitors as anticancer agents
03/06/2014WO2014032398A1 Pyridazinone compound, preparation method, pharmaceutical composition and use thereof
03/06/2014WO2014015235A3 3,5,n-trihydroxy-alkanamide and derivatives: method for making same and use thereof
03/06/2014WO2014008838A4 Bis-indolylacetic acid derivative attached with aryl substituted methyl, and preparation method and use thereof
03/06/2014WO2014007951A3 Substituted tricyclic compounds as fgfr inhibitors
03/06/2014WO2014004902A3 Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof
03/06/2014WO2013190510A3 NOVEL 2,3-DIHYDRO-1H-IMIDAZO{1,2-a}PYRIMIDIN-5-ONE and this1,2,3,4-TETRAHYDROPYRIMIDO{1,2-a}PYRIMIDIN-6-ONE DERIVATIVES COMPRISING A SUBSTITUTED MORPHOLINE, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF
03/06/2014WO2013106485A3 Ultralong complementarity determining regions and uses thereof
03/06/2014US20140066495 Transmucosal administration of taxanes
03/06/2014US20140065189 Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
03/06/2014US20140065160 Combination therapy
03/06/2014US20140065148 Treatment methods using antibodies to aminophospholipids
03/06/2014DE102012017516A1 New 1-aryloxy-3-pyrrol-1-yl-propan-2-one derivatives are cytosolic phospholipase A2 inhibitors, useful for prophylactic or therapeutic treatment of diseases caused by increased activity of phospholipase A2, preferably e.g. pain and fever
03/05/2014EP2703486A1 Anti-b7-h3 antibody
03/05/2014EP2703410A1 Jagaricin, derivatives, and uses thereof
03/05/2014EP2703407A1 Method for manufacturing phosphonocrotonic acid derivative
03/05/2014EP2703006A1 Use of regulator of calcineurin 1 for manufacturing medicament for treatment of diseases associated with increased nf- b activity
03/05/2014EP2703005A1 Inhibitors of alpha6 Integrin/E-Cadherin Complex
03/05/2014EP2702997A1 Method and composition for enhancing target cells uptake of therapeutic agents
03/05/2014EP2702155A1 Microrna compounds and methods for modulating mir-21 activity
03/05/2014EP2702145A1 Methods for preparing accessory cells and uses thereof for preparing activated nk cells
03/05/2014EP2702078A2 Anti-cd40 antibodies and methods of use
03/05/2014EP2702069A2 Il4/il13 binding repeat proteins and uses
03/05/2014EP2702063A1 Bicyclic pyridazine compounds as pim inhibitors
03/05/2014EP2702061A1 Pyrrolotriazinone derivatives as pi3k inhibitors
03/05/2014EP2702055A1 Pyrazolyl-pyrimidine derivatives as kinase inhibitors
03/05/2014EP2702052A1 17alpha-hydroxylase/c17,20-lyase inhibitors
03/05/2014EP2702043A1 Inhibitors of inducible form of 6-phosphofructose-2-kinase
03/05/2014EP2702030A1 Compositions and methods
03/05/2014EP2701741A1 Dosage regimen for administering a cd19xcd3 bispecific antibody to patients at risk for potential adverse effects
03/05/2014EP2701724A1 Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-fu) and irinocetan (folfiri)
03/05/2014EP2701722A2 Human myeloid derived suppressor cell cancer markers
03/05/2014EP2701720A1 Lyophilized preparation of cytotoxic dipeptides
03/05/2014EP2701708A2 Small molecule trail gene induction by normal and tumor cells as an anticancer therapy
03/05/2014EP2701703A1 Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor
03/05/2014EP2701700A1 Drug therapy to inhibit chemotherapy-induced adverse effects and related pharmaceutical compositions, diagnostics, screening techniques and kits
03/05/2014EP2701692A1 Methods and pharmaceutical compositions for the treatment of hormone-refractory prostate cancers
03/05/2014EP2701690A1 Method of treating lymphoma using pyridopyrimidinone inhibitors of pi3k/mtor
03/05/2014CN103620035A Microrna compounds and methods for modulating mir-21 activity
03/05/2014CN103620033A SEMA5B peptides and vaccines including the same
03/05/2014CN103620022A Method for amplifying nk cells
03/05/2014CN103619879A Anti-ngf compositions and use thereof
03/05/2014CN103619874A Soluble integrin [alpha]4 mutant
03/05/2014CN103619865A Certain chemical entities, compositions, and methods
1 ... 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 ... 2211